Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001493152-25-007178
Filing Date
2025-02-18
Accepted
2025-02-18 16:15:05
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6007
  Complete submission text file 0001493152-25-007178.txt   7764
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Subject) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-81115 | Film No.: 25635053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address SPERLRING 2 PFAFFENHOFEN 2M 85276
Business Address SPERLRING 2 PFAFFENHOFEN 2M 85276 498441 78644 14
Orca Capital AG (Filed by) CIK: 0002052389 (see all company filings)

EIN.: 000000000 | State of Incorp.: 2M | Fiscal Year End: 1231
Type: SCHEDULE 13G/A